Rudy Li
Stock Analyst at Wolfe Research
(4.97)
# 21
Out of 5,149 analysts
39
Total ratings
72.97%
Success rate
90.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | $40 | $26.20 | +52.67% | 5 | Feb 24, 2026 | |
| ALKS Alkermes | Initiates: Outperform | $45 | $29.20 | +54.11% | 1 | Feb 24, 2026 | |
| AXSM Axsome Therapeutics | Initiates: Outperform | $230 | $164.05 | +40.20% | 1 | Feb 24, 2026 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $60 | $43.79 | +37.02% | 5 | Feb 24, 2026 | |
| STOK Stoke Therapeutics | Initiates: Outperform | $40 | $33.78 | +18.41% | 5 | Feb 24, 2026 | |
| QURE uniQure | Initiates: Peer Perform | n/a | $9.03 | - | 1 | Feb 24, 2026 | |
| DNLI Denali Therapeutics | Initiates: Peer Perform | n/a | $20.02 | - | 1 | Feb 24, 2026 | |
| PRAX Praxis Precision Medicines | Initiates: Outperform | $500 | $318.22 | +57.12% | 4 | Feb 24, 2026 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $160 | $131.14 | +22.01% | 1 | Feb 24, 2026 | |
| DFTX Definium Therapeutics | Initiates: Outperform | $25 | $17.69 | +41.32% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $22.50 | +46.67% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $80.00 | - | 3 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $1.07 | +180.37% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $20.11 | -25.41% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2 | $0.22 | +828.94% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 | $9.36 | +92.31% | 7 | Aug 28, 2025 |
Centessa Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $26.20
Upside: +52.67%
Alkermes
Feb 24, 2026
Initiates: Outperform
Price Target: $45
Current: $29.20
Upside: +54.11%
Axsome Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $230
Current: $164.05
Upside: +40.20%
Xenon Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $60
Current: $43.79
Upside: +37.02%
Stoke Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $33.78
Upside: +18.41%
uniQure
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $9.03
Upside: -
Denali Therapeutics
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $20.02
Upside: -
Praxis Precision Medicines
Feb 24, 2026
Initiates: Outperform
Price Target: $500
Current: $318.22
Upside: +57.12%
Neurocrine Biosciences
Feb 24, 2026
Initiates: Outperform
Price Target: $160
Current: $131.14
Upside: +22.01%
Definium Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $25
Current: $17.69
Upside: +41.32%
Feb 24, 2026
Initiates: Outperform
Price Target: $33
Current: $22.50
Upside: +46.67%
Jan 2, 2026
Maintains: Buy
Price Target: $80
Current: $80.00
Upside: -
Sep 29, 2025
Initiates: Buy
Price Target: $3
Current: $1.07
Upside: +180.37%
Sep 29, 2025
Initiates: Buy
Price Target: $15
Current: $20.11
Upside: -25.41%
Sep 29, 2025
Initiates: Buy
Price Target: $2
Current: $0.22
Upside: +828.94%
Aug 28, 2025
Maintains: Buy
Price Target: $18
Current: $9.36
Upside: +92.31%